ARVN vs PBYI: stock comparison and AI forecast
Arvinas, Inc. (ARVN) and Puma Biotechnology, Inc. (PBYI) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ARVN Arvinas, Inc.
- Market Cap
- $419M
- P/E Ratio
- 5.8x
- Size
- small-cap
- AI Forecast
PBYI Puma Biotechnology, Inc.
- Market Cap
- $426M
- P/E Ratio
- 12.7x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ARVN and PBYI have similar market capitalizations ($419M and $426M).
- ARVN trades at 5.8 times trailing earnings, PBYI at 12.7 times.
- PBYI carries 0.39 times debt per unit of equity, against 0.18 times for ARVN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ARVN | PBYI |
|---|---|---|
| Market Cap | $419M | $426M |
| P/E Ratio | 5.83x | 12.69x |
| P/B Ratio | 0.82x | 3.07x |
| EPS | $1.10 | $0.65 |
| Book Value/Share | $7.86 | $2.68 |
| Revenue/Share | $3.97 | $4.48 |
| FCF/Share | $-2.44 | $0.80 |
Profitability & Margins
| Metric | ARVN | PBYI |
|---|---|---|
| ROE | – | 19.3% |
| ROA | – | 13.9% |
| ROIC | -6.2% | 21.3% |
| Gross Margin | – | 74.8% |
| Operating Margin | -12.9% | 13.2% |
| Net Margin | – | 11.6% |
| EBT Margin | -3.4% | 13.5% |
| Tax Rate | -6.7% | 13.7% |
Financial Health
| Metric | ARVN | PBYI |
|---|---|---|
| Current Ratio | 8.39x | 2.91x |
| Quick Ratio | – | 2.64x |
| D/E Ratio | 0.18x | 0.39x |
| Financial Leverage | 1.18x | 1.39x |
| Interest Coverage | 10.8x | 10.0x |
| Working Capital | $518M | $95M |
Cash Flow
| Metric | ARVN | PBYI |
|---|---|---|
| Operating Cash Flow | -$158M | $41M |
| Free Cash Flow | -$160M | $41M |
| Capital Spending | -$2M | $10K |
| OCF Growth YoY | – | -7.2% |
| FCF Growth YoY | – | -6.9% |
| FCF/Sales | -61.5% | 17.8% |
| CapEx/Sales | 0.6% | 0.0% |
Operational Efficiency
| Metric | ARVN | PBYI |
|---|---|---|
| Asset Turnover | 0.43x | 1.20x |
| Receivables Turnover | 144.3x | 6.8x |
| Inventory Turnover | – | 4.4x |
| Fixed Assets Turnover | 56.5x | 2245.1x |
| Days Sales Outstanding | 3 days | 54 days |
| Days Inventory | – | 84 days |
| Payables Period | – | 19 days |
| Cash Conversion Cycle | – | 118 days |
Income Statement
| Metric | ARVN | PBYI |
|---|---|---|
| Total Revenue | $260M | $231M |
| Operating Income | -$34M | $30M |
| Net Income | – | $27M |
| R&D Expense | $221M | $71M |
| SG&A Expense | – | $71M |
| Cost of Goods Sold | – | $58M |
Dividend & Shareholder Information
| Metric | ARVN | PBYI |
|---|---|---|
| Shares Outstanding | 65M | 52M |
| Net Income Growth | – | -44.9% |
| EPS Growth | – | -21.7% |
ARVN vs PBYI: stock comparison and AI forecast
Which is bigger, ARVN or PBYI?
ARVN and PBYI have similar market capitalizations ($419M and $426M).
Which is cheaper on earnings, ARVN or PBYI?
ARVN trades at 5.8 times trailing earnings, PBYI at 12.7 times.
Which one does Intratio's AI model rank higher, ARVN or PBYI?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.